Konda SK, Maliki R, McGrath S, Parker BS, Robinson T, Spurling A, Cheong A, Lock P, Pigram PJ, Phillips DR, Wallace L, Day AI, Collins JG and Cutts SM (2017) Encapsulation of mitoxantrone within cucurbituril decreases toxicity and enhances survival in a mouse model of cancer, ACS Med Chem Lett., 8(5): 538-542.
Tarasenko N, Nudelman A, Rozic G, Cutts SM and Rephaeli A (2017) Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenografts, Invest New Drugs, 35(4): 412-426.
Konda SK, Kelso C, Medan J, Sleebs BE, Phillips DR, Cutts SM and Collins JG (2016) Isolation and structural analysis of the covalent adduct formed between a bis-amino mitoxantrone analogue and DNA: a pathway to major-minor groove cross-linked adducts, Org Biomol Chem., 14(43): 10217-21.
Konda SK, Kelso C, Pumuye PP, Medan J, Sleebs BE, Cutts SM, Phillips DR, Collins JG (2016) Reversible and formaldehyde-mediated covalent binding of a bis-amino mitoxantrone analogue to DNA, Org Biomol Chem., 14(20): 4728-38.
Evison BJ, Sleebs BE, Watson KG, Phillips DR and Cutts SM (2016) Mitoxantrone, more than just another Topoisomerase II poison, Med Res Rev., 36: 248-99.
Cutts SM, Rephaeli A, Nudelman A, Ugarenko M and Phillips DR (2015) Potential therapeutic advantages of doxorubicin when activated by formaldehyde to function as a DNA adduct-forming agent, Curr Top Med Chem., 15: 1409-22.
Shekhar TM, Green MM, Rayner DM, Miles MA, Cutts SM and Hawkins CJ (2015) Inhibition of Bcl-2 or IAP proteins does not provoke mutations in surviving cells, Mut Res., 777: 23-32.
Konda SK, Wang H, Cutts SM, Phillips DR and Collins JG (2015) Binding of pixantrone to DNA at CpA dinucleotide sequences and bulge structures, Org Biomol Chem., 13(21): 5972-82.
Tarasenko N, Cutts SM, Phillips DR, Berkovitch-Luria G, Bardugo-Nissim E, Weitman M, Nudelman A and Rephaeli A (2014) A novel valproic acid prodrug as an anticancer agent that enhances doxorubicin anticancer activity and protects normal cells against its toxicity in vitro and in vivo, Biochem Pharmacol., 88(2): 158-68.
Ankers EA, Evison BJ, Phillips DR, Brownlee RTC and Cutts SM (2014) Design, synthesis, and DNA sequence selectivity of formaldehyde-mediated DNA-adducts of the novel N-(4-aminobutyl) acridine-4-carboxamide, Bioorg Med Chem Lett., 24(24): 5710-15.
Rayner DM and Cutts SM (2014) Anthracyclines, The Side Effects of Drug Annual, 36: 683-94.
Forrest RA, Swift LP, Evison BJ, Rephaeli A, Nudelman A, Phillips DR and Cutts SM (2013) The hydroxyl epimer of doxorubicin controls the rate of formation of cytotoxic anthracycline-DNA adducts, Cancer Chemother Pharmacol., 71(3): 809-16.
Forrest RA, Swift LP, Rephaeli A, Nudelman A, Kimura K-I, Phillips DR and Cutts SM (2012) Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation, Biochem Pharmacol., 83(12): 1602-12.
Bilardi RA, Kimura K-I, Phillips DR and Cutts SM (2012) Processing of anthracycline-DNA adducts via DNA replication and interstrand crosslink repair pathways, Biochem Pharmacol., 83(9): 1241-50.
Tarasenko N, Cutts SM, Phillips DR, Inbal A, Kessler-Icekson G-I, Nudelman A and Rephaeli A (2012) Disparate impact of butyroyloxymethyl diethylphosphate (AN-7), a histone deacetylase inhibitor, and doxorubicin in mice bearing a mammary tumor, PLoS One, 7(2): e31393.
Tarasenko N, Kessler-Icekson G, Boer P, Inbal A, Schlesinger H, Phillips DR, Cutts SM, Nudelman A and Rephaeli A (2012) The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity, Invest New Drugs, 30(1): 130-43.
Evison BJ, Pastuovic M, Bilardi RA, Forrest RA, Pumuye PP, Sleebs BE, Watson KG, Phillips DR and Cutts SM (2011) M2, a novel anthracenedione, elicits a potent DNA damage response that can be subverted through checkpoint kinase inhibition to generate mitotic catastrophe, Biochem Pharmacol., 82(11): 1604-18.